Beyond The Numbers: 6 Analysts Discuss Ardent Health Partners Stock
In the preceding three months, 6 analysts have released ratings for Ardent Health Partners (NYSE:ARDT), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 1 | 0 | 0 |
| 3M Ago | 0 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.5, a high estimate of $25.00, and a low estimate of $19.00. Highlighting a 2.17% decrease, the current average has fallen from the previous average price target of $23.00.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Ardent Health Partners's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Benjamin Rossi | JP Morgan | Announces | Neutral | $20.00 | - |
| Ben Hendrix | RBC Capital | Maintains | Outperform | $23.00 | $23.00 |
| Whit Mayo | Leerink Partners | Raises | Outperform | $25.00 | $23.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Neutral | $19.00 | $22.00 |
| Matthew Gillmor | Keybanc | Announces | Overweight | $24.00 | - |
| Scott Fidel | Stephens & Co. | Maintains | Overweight | $24.00 | $24.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ardent Health Partners. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ardent Health Partners compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Ardent Health Partners's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Ardent Health Partners's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Ardent Health Partners analyst ratings.
Delving into Ardent Health Partners's Background
Ardent Health Partners Inc is an operator of hospitals and a provider of healthcare services in the United States. It provide both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. The company has one reportable segment: healthcare services that provides healthcare services primarily through its ownership and operation of hospitals, certain of which provide related healthcare services through physician practices, outpatient centers, and post-acute facilities. Ardent has 30 acute care hospitals, more than 200 sites of care that operates across six states: Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas.
Ardent Health Partners: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Ardent Health Partners's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 5.23%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ardent Health Partners's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 1.82%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.02%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ardent Health Partners's ROA excels beyond industry benchmarks, reaching 0.56%. This signifies efficient management of assets and strong financial health.
Debt Management: Ardent Health Partners's debt-to-equity ratio is below the industry average at 2.24, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.